

1 **Exercise priming to enhance therapeutic bond and behavioral activation in CBT for**
2 **MDD: a randomized controlled target-engagement trial with remission signal**

3
4 Jacob D. Meyer^{a,b}, Shania J. E. Kelly^a, John M. Gidley^a, Jeni E. Lansing^a, Seana L. Smith^a,
5 Sydney L. Churchill^b, Madeleine L. Connolly^a, Emily B. K. Thomas^c, Simon B. Goldberg^{d,e},
6 Heather C. Abercrombie^c, Thomas A. Murray^f, Nathaniel G. Wade^g

7
8 ^a Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, USA

9 ^b Department of Kinesiology, Iowa State University, Ames, IA, USA

10 ^c Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA, USA

11 ^d Department of Counseling Psychology, University of Wisconsin-Madison, Madison, WI,
12 USA

13 ^e Center for Healthy Minds, University of Wisconsin-Madison, Madison, WI, USA

14 ^f Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis,
15 MN, USA

16 ^g Department of Psychology, Iowa State University, Ames, IA, USA

17
18 Corresponding Author:

19 Jacob D. Meyer

20 E-mail address: jdmeyer3@wisc.edu

21 **Abstract**

22 Major depressive disorder (MDD) is a debilitating condition with frequent relapses.
23 Augmentation strategies may improve psychotherapy outcomes, particularly if they enhance
24 mechanisms of change. Using an experimental therapeutics approach, this pilot trial evaluated
25 whether 30 minutes of individual moderate exercise immediately before individual cognitive
26 behavioral therapy (ActiveCBT) engages two mechanistic targets (behavioral activation and
27 therapeutic alliance) compared to a time- and attention-matched control (CalmCBT). Forty
28 adults with DSM-5 MDD were severity-stratified and randomized to 8 weeks of ActiveCBT
29 (n=19) or CalmCBT (n=21). Primary outcomes were the Working Alliance Inventory–Short
30 Revised (WAI; Bond, Task, Goals subscales) and Behavioral Activation for Depression Scale
31 (BADs). Depression outcomes included Hamilton Rating Scale for Depression (HAM-D)
32 response ($\geq 50\%$ reduction) and remission (HAM-D < 8) from a masked assessor. Generalized
33 estimating equations estimated group effects across time, standardized as Cohen’s d , with a
34 priori success defined as $d \geq 0.35$ for both or $d \geq 0.55$ for either WAI or BADs. The average
35 standardized effect for WAI-Bond favoring ActiveCBT was $d=0.36$ (95% CI: -0.19, 0.90,
36 $p=0.20$) and BADs was $d=0.43$ (-0.07, 0.94; $p=0.09$). Secondary exploratory analyses found a
37 significant remission benefit for ActiveCBT over CalmCBT (69% vs 33%, $p<0.05$), with
38 similar response rates. Exercise priming demonstrated directional mechanistic signals in both
39 specific (behavioral activation) and nonspecific (therapeutic bond) targets, with potential
40 remission benefits from exploratory analyses. These findings preliminarily suggest that
41 exercising before therapy could augment CBT and offer a safe, accessible way to potentially
42 boost its antidepressant effects.

43

44 **Clinical Trial Registration:** This study was prospectively registered at ClinicalTrials.gov
45 (NCT06001346).

46 **Keywords:** exercise; depression treatment; therapy augmentation; treatment innovation;

47 treatment mechanisms.

48

49 **Introduction**

50 Treatment of major depressive disorder (MDD), a common and debilitating disease
51 (Kessler et al., 2012), is difficult. Just half of patients respond to front-line treatments for
52 depression (Cuijpers et al., 2014), and relapses are common (Lemmens et al., 2019; Vittengl
53 et al., 2007). Although psychotherapies and medications can be effective in treating
54 depression (Cuijpers et al., 2021, 2020), there is substantial room to improve their efficacy.
55 Augmentation approaches for treatment may hold the key to enhancing success rates
56 (Strawbridge et al., 2019), particularly as augmentation is becoming more common in clinical
57 practice. Determining how augmentation strategies influence the known mechanisms of
58 change of current interventions is a critical first step in assessing strategies that may enhance
59 treatment success and consistent with the experimental therapeutics approach whereby
60 mechanism engagement must first be confirmed prior to large-scale efficacy trials (Zucker et
61 al., 2025).

62 Decades of psychotherapy research have identified key process factors (both specific
63 and nonspecific) that reliably predict treatment success in cognitive behavioral therapy
64 (CBT). These factors include processes that are specific to CBT (i.e., only important for CBT)
65 and nonspecific (i.e., important for any therapy) (Cuijpers et al., 2019b; Huibers and Cuijpers,
66 2015; Lorenzo-Luaces et al., 2015; Manos et al., 2010). Consistent predictors of CBT's
67 antidepressant effects are high behavioral activation as the result of sessions (specific to CBT)
68 (Alexopoulos et al., 2016) and the creation or development of a strong working alliance
69 between the client and the therapist (nonspecific) (Arnow et al., 2013). Better engagement of
70 these mechanisms of change should predict greater treatment effects; therefore, augmentation
71 strategies that increase engagement of these process targets could be transformative.

72 Harnessing the acute benefits of exercise is a novel and potentially impactful way to
73 improve therapy mechanisms of change. We have shown that a single session of moderate

74 intensity cycling exercise increases markers of neuroplasticity (e.g., brain-derived
75 neurotrophic factor (BDNF) (Meyer et al., 2016a)) and improves the primary symptoms of
76 depression (depressed mood state and state anhedonia (Meyer et al., 2016b, 2022a)) in adults
77 experiencing a major depressive episode, with greater neuroplastic potential and lower
78 symptoms related to treatment success (Khazanov et al., 2020; Polyakova et al., 2015). We
79 have developed an exercise priming of therapy approach (i.e., exercise right before each
80 therapy session), finding in our randomized controlled n=10 pilot that exercise priming of
81 CBT led to greater working alliance and behavioral activation across treatment (Hedges' $g =$
82 1.10 and 1.40, respectively) (Meyer et al., 2022b). This aligns with initial small-sample
83 research investigating the beneficial effects of exercise priming in other conditions (e.g., post-
84 traumatic stress disorder) (Bryant et al., 2023) and intervention modalities (e.g., group-based
85 psychotherapy) (Schmitter et al., 2025). Exercise priming holds significant promise for
86 improving therapy effectiveness for depression, yet rigorous research focused on mechanisms
87 of change is needed to lay the foundation for future trials targeting clinical benefits.

88 Acute aerobic exercise has well-documented effects on cognitive and emotional
89 systems relevant to psychotherapy which could be involved in enhancement in alliance and
90 activation. First, exercise can reduce stress reactivity and improve emotion regulation
91 (Morava et al., 2024; Wang et al., 2024), creating a psychological state conducive to openness
92 and disclosure. In clinical contexts, single exercise sessions improve social interaction and
93 mood among psychiatric inpatients (Brand et al., 2018), suggesting that exercise may prime
94 interpersonal engagement in difficult conversations and trust which are key components of
95 developing a strong therapeutic alliance. Second, a single bout of moderate exercise enhances
96 executive function and attentional control (Chang et al., 2025), which may help clients sustain
97 focus and engage more fully in cognitively demanding CBT tasks in-session.

98 Neurobiologically, exercise increases cerebral blood flow and neuroplasticity markers such as

99 BDNF (Meyer et al., 2016a), supporting learning and memory processes critical for acquiring
100 CBT skills and implementing activation strategies. Collectively, these mechanisms provide a
101 plausible basis for hypothesizing that exercise priming could enhance both nonspecific
102 (therapeutic bond) and specific (behavioral activation) processes that predict antidepressant
103 response from CBT.

104 The present pilot and target engagement double-blind (therapist, assessor) trial was
105 designed to evaluate the potential for exercise priming augmentation of CBT (termed
106 “ActiveCBT”) to better engage important mechanisms of change in CBT (working alliance
107 and behavioral activation) compared to a closely matched comparator condition (termed
108 “calm priming” and CalmCBT) across an 8-week manualized CBT program. In line with the
109 National Institute of Mental Health’s experimental therapeutics approach (Zucker et al.,
110 2025), this trial was designed to detect directional engagement of mechanisms of change via
111 the ActiveCBT condition (i.e., greater working alliance and behavioral activation as important
112 steps to enhancing the efficacy of CBT) and not powered for clinical efficacy testing. As a
113 result, changes in interviewer-assessed depression and remission were evaluated only as
114 secondary, exploratory outcomes. The *a priori*-defined and pre-registered rule for progressing
115 to a larger trial was to find a standardized effect (i.e., similar to Cohen’s *d* (Cohen, 1969))
116 favoring ActiveCBT on both primary outcomes of working alliance and behavioral activation
117 ≥ 0.35 standard deviation or either one at ≥ 0.55 standard deviation (Meyer et al., 2024).

118 **Methods**

119 ***Study Design and Participants***

120 This study was a 1:1 severity-stratified (mild, moderate-to-severe) parallel-group
121 randomized controlled clinical trial of ActiveCBT (pre-therapy exercise) vs. CalmCBT (quiet
122 rest pre-therapy) for the treatment of major depression with masked assessors and
123 interventionists called the ‘CBT+ Study.’ Methods for the present trial have been registered in

124 a published protocol paper (Meyer et al., 2024) and at ClinicalTrials.gov (NCT06001346) and
125 recruitment ran from September 2023 until August 2024 and ended after filling the 40-person
126 randomization target. Methods and procedures reported below are those relevant to the
127 primary outcome analyses (working alliance and behavioral activation) and reporting of the
128 overall effects on depression across the initial 8-week treatment. This study was approved by
129 the local Institutional Review Board (#23–026-00). All participants provided electronic,
130 written informed consent to participate.

131 Participants (n=40) were recruited via referral from university and community partners
132 (i.e., student counseling services, on-campus medical clinic, therapist wait-lists, and
133 surrounding clinics), mass emails, flyers, and contacts in large corporations in Ames, Iowa
134 and surrounding communities. To be included in the sample, participants were diagnosed with
135 major depressive disorder and in a major depressive episode via the Structured Clinical
136 Interview for Depression (SCID), had at least mild clinical symptoms of depression
137 (Hamilton Rating Scale for Depression [HAM-D] ≥ 8), aged 18-65, on a stable mental health
138 medication or psychotherapy treatment regimen for at least eight weeks, willing to refrain
139 from changing mental health treatment for the duration of the intervention, had not
140 participated in structured CBT in the past 5 years, and reported they could safely participate in
141 physical activity (via Physical Activity Readiness Questionnaire). Exclusion criteria were:
142 body mass index ≥ 40 ; pose an imminent risk of harm to others or self-harm (Columbia
143 Suicide Severity Rating Scale of 5); current substance use disorder; lifetime bipolar, mania, or
144 psychosis; pregnant or planning to become pregnant during study enrollment; currently used
145 tobacco or other nicotine products; or exhibited behavioral disturbance (e.g., aggression,
146 mild-moderate cognitive impairment) that would significantly interfere with study
147 participation, as assessed by clinical research personnel during intake.

148 ***Study Flow***

149 See **Figure 1** for the CONSORT diagram. All interested participants completed an
150 online screening survey via REDCap (n=379) followed by a subsequent phone screening
151 performed by senior research staff that determined potential eligibility. Participants that met
152 preliminary eligibility criteria during the phone screening were invited to an in-person intake
153 visit (n=84) consisting of an informed consent, tour of the facilities, clinical interview to
154 confirm eligibility, and a series of questionnaires including demographics. Interviewers were
155 senior Counseling Psychology Ph.D. students or trained clinical interviewers with at least a
156 bachelor's degree in psychology with structured training on diagnosis and assessment using
157 the SCID and supervised by a licensed psychologist [NW]. Eligible participants began their 8
158 weekly visits roughly one week after their intake visit (n=40). At the start of the first therapy
159 visit, randomization to ActiveCBT and CalmCBT groups occurred via severity-stratified
160 (mild vs. moderate-to-severe; HAMD <18 vs. 18+) blocked randomization using the REDCap
161 randomization module based on a pre-specified randomization schedule generated and
162 uploaded by the study statistician. After completing the 8-weekly therapy sessions,
163 participants came back for a post-intervention visit roughly one week following their eighth
164 therapy session. The post-intervention visit included a clinical interview and a series of
165 questionnaires. All therapy sessions and the post-intervention visit occurred within 12 weeks
166 of the intake visit.

167 *Pre-Therapy Conditions*

168 Pre-therapy, individuals randomized to ActiveCBT completed 30 minutes of cycling
169 on a recumbent stationary bicycle (Lode Corival Recumbent, Lode BV, Groningen, The
170 Netherlands) at moderate intensity (rating of perceived exertion [RPE] of 13 on the 6-20 scale
171 (Borg, 1998)) while individuals in the CalmCBT condition sat quietly (RPE of 6).
172 Standardized instructions for RPE were provided to all participants. All participants were
173 asked to report their RPE and heart rate (Polar H10, Polar Electro Oy, Kempele, Finland) was

174 recorded every minute for the first 3 minutes (ActiveCBT warm-up), at 5-minute increments
175 starting at minute 5, and then at every minute for the last 3 minutes starting at minute 27
176 (ActiveCBT cool-down). ActiveCBT participants were instructed to achieve a moderate
177 intensity to coincide with the end of the 3-minute warm-up and maintain that intensity by self-
178 adjusting the workload until cool-down. Exercise workload (e.g., watts, cadence) was
179 recorded at the same intervals for ActiveCBT participants.

180 Both the ActiveCBT and CalmCBT conditions were presented with equipoise, and
181 each participant was aware that they may be randomly assigned to either condition. Each
182 condition was described simply as a pre-therapy condition, and participants were informed
183 that the study aimed to examine how these experiences might influence therapy. To provide a
184 standardized experience across conditions, all participants watched 30 minutes of a
185 standardized nature video.

186 *Nature Videos*

187 All participants watched a standard 30-minute segment from the nature documentary,
188 Blue Planet II, Season 1 (*Blue planet II*, 2017). This was selected as it provided a neutral
189 video stimulus, was available for the duration of the study, and a new segment could be used
190 for all 8 study visits with episodes and start times in the protocol paper (Meyer et al., 2024).

191 *Therapy Sessions*

192 Following the pre-therapy condition, participants completed questionnaires prior to the
193 start of their therapy session. Ten minutes post-condition, participants began a 50-minute
194 standardized therapy session with a trained mental health counselor, masked from group
195 assignment. Each session had a theme and was standardized based upon the CBT manual
196 developed by the South Central MIRECC (Cully and Teten, 2008). Additional content details
197 are provided in the protocol paper. Each session was audio and video recorded using Lyssn
198 (Lyssn, Seattle, WA), for ongoing supervision and fidelity checks. The Lyssn platform

199 provides an algorithm-generated rating score for the Cognitive Therapy Rating Scale (CTRS
200 (Young and Beck, 1980)) using an artificial intelligence-trained machine learning model
201 based on the conversational content within each recorded session (e.g., (Imel et al., 2024)).
202 Participants were instructed to not discuss their assigned pre-therapy condition/group
203 assignment during therapy or clinical assessments with any incidental disclosure recorded.
204 Therapists and clinical interviewers provided their best guess to condition assignment of each
205 participant post-intervention. Immediately following each therapy session, participants
206 completed a series of questionnaires.

207 *Primary Measures*

208 Working alliance and behavioral activation were the *a priori*-selected primary
209 outcomes for the present study. Working alliance related to each session was recorded
210 following each therapy session via the client version of the Working Alliance Inventory –
211 Short Revised (WAI) (Hatcher and Gillaspay, 2006). The WAI is a 12-item assessment
212 utilizing a 5-point Likert-scale ranging from 1 (seldom) to 5 (always). The survey is scored
213 via three 4-item subscales for components of the therapeutic alliance: bond (the quality of the
214 emotional bond between patient and therapist), goals (the agreement between the client and
215 therapist on the goals of treatment), and task (the agreement between the client and therapist
216 on the tasks to achieve the goals), as well as with a total, or sum, score with higher scores
217 indicating greater patient-therapist alliance.

218 Behavioral activation over the preceding week was assessed at intake, the start of each
219 therapy session, and the post-intervention visit using the Behavioral Activation for Depression
220 Scale (BADs) (Kanter et al., 2006). The BADs consists of 25 questions asking about
221 activation, avoidance/rumination, work/school impairment, and social impairment occurring
222 over the past week. The BADs is scored using a total score with higher scores indicating
223 greater behavioral activation. The change in BADs from the baseline score at week 1 (which

224 reflected activation in the week preceding the start of treatment) to each subsequent
225 assessment at weeks 2-8 and the post-intervention visit (each reflecting activation in the
226 preceding week corresponding to activation in response to each of the therapy sessions) was
227 the primary outcome of interest.

228 ***Secondary Outcomes***

229 *Clinical Outcomes*

230 Depression diagnoses were made via the SCID at the intake visit and post-intervention
231 visit. The clinician-rated Hamilton Depression Rating Scale (HAMD) and the Columbia
232 Suicide Severity Rating Scale (C-SSRS) were also completed at these time. The SCID is a
233 semi-structured interview used to diagnose mental disorders according to the diagnostic
234 criteria published within the American Psychiatric Association's Diagnostic and Statistical
235 Manual for Mental Disorders (DSM-5 (First et al., 2015)). The HAMD was administered to
236 assess depression symptom severity utilizing the 17-item GRID – HAMD scale recording
237 severity of depressed mood, feelings of guilt, suicidal ideation, insomnia, agitation or
238 retardation, anxiety, weight loss and somatic symptoms (Hamilton, 1967; Williams et al.,
239 2008). The assessment uses a sum score with higher scores indicating greater symptom
240 severity categorized as: no depression (0-7), mild depression (8-16), moderate depression (17-
241 23), and severe depression (≥ 24) (Zimmerman et al., 2013). The C-SSRS (Posner et al., 2008)
242 was administered at all study visits to assess any suicidality concerns and to engage mitigation
243 practices, if appropriate. A safety plan was developed during the intake that was referenced
244 and revised, as appropriate, throughout the intervention.

245 Additionally, the Patient Health Questionnaire-9 (PHQ-9) (Kroenke et al., 2001) was
246 completed by the participant at every visit. The PHQ-9 was created based on the DSM-IV
247 depression criteria with each question ranging from 0 (not at all) to 3 (nearly every day) with
248 a total score ranging from 0 to 27.

249 *Additional Session Measures*

250 In addition to working alliance, the Session Evaluation Questionnaire (SEQ) (Stiles,
251 1980), an additional measure of in-session processes, and the Automatic Thoughts
252 Questionnaire (ATQ) (Hollon and Kendall, 1980), a measure of the believability of automatic
253 negative thoughts, were recorded as additional assessments of exercise priming. The SEQ was
254 completed by the participant following each therapy session, and the ATQ was completed at
255 the start of each visit.

256 *Other Assessments*

257 Additional mental health and quality of life assessments were collected at baseline,
258 and throughout the study: DSM-5 Level 1 Cross-Cutting Symptoms Measure, WHO
259 Disability Assessment Schedule, Quality of Life, GAD-7, Adverse Childhood Experiences,
260 Intervention Satisfaction, and Nature Connectedness Inventory (Meyer et al., 2024). Blood
261 draws were also completed at weeks 1, 4, and 8 at three separate times on each visit (before
262 the Active/Calm condition, between the condition and the therapy session, and after the
263 therapy session).

264 *Adverse Event Reporting*

265 Adverse events were systematically documented on REDCap after each study visit by
266 the research team. Briefly, the research team would select “Yes” or “No” based on if a
267 potentially reportable event was disclosed by the participant or research team during the study
268 visit. If “Yes” was selected, a Reportable Event Monitoring Form detailing the event was
269 completed. During the post-intervention visit, participants responded to the prompt, “Have
270 you experienced changes in medical conditions since you’ve started this trial that is/are
271 potentially related to your enrollment in the study?” Participants were asked to provide detail
272 via free text response with follow-up performed according to reporting requirements.

273 *Statistical Analysis*

274 The sample size was chosen to ensure a high probability for achieving the study
275 progression criteria for target engagement for mechanisms of change under the expected
276 effects of $d \geq 0.50$ and a low probability for achieving the Go criteria when $d=0$ with a
277 conservative 80% retention. Progression criteria were based on NIH experimental therapeutics
278 guidance to determine mechanistic plausibility before scaling to efficacy. The probability of
279 achieving the progression criteria (observing $d \geq 0.35$ on both WAI and BADS or $d \geq 0.55$ on at
280 least one) if true target engagement was absent on both endpoints ($d=0$), was low (<2%
281 chance), and conversely if true target engagement is moderate on both endpoints ($d \geq 0.5$) or
282 strong ($d \geq 0.75$) on one endpoint, then the progression criteria was likely to be achieved
283 (>74% chance).

284 All analyses were conducted following the intention-to-treat (ITT) principle and
285 included outcome data from all randomized participants including those who did not complete
286 all 8 therapy sessions. Due to the sample size and generally limited missingness for a clinical
287 trial, we did not attempt to multiply impute missing outcome data and instead conducted
288 analyses using all available observed data.

289 To estimate condition effects (i.e. ActiveCBT versus CalmCBT) on the WAI overall
290 score across therapy sessions at weeks 1 to 8, we used a generalized estimating equation
291 (GEE) with an AR(1) working correlation matrix and factorial session by condition effects.
292 We then averaged the session specific condition effects across the 8 weeks, and obtained the
293 standardized average condition effect estimate by dividing by the estimated residual standard
294 deviation. Our emphasis was on effect size rather than statistical significance testing per the
295 funding mechanism for this trial. Estimates of condition effects on the three WAI subscales
296 were obtained similarly. We conducted an analysis of change in BADS total score from week

297 1 across weeks 2 to 8 and the post-intervention visit similarly using a GEE but also adjusted
298 for the week 1 (pre-condition) BADS total score.

299 To understand which items on the WAI questionnaire were implicated in any
300 condition effects, we used mixed models with participant and session within-participant
301 random effects to conduct item-specific analyses (i.e., each item from the WAI was a repeated
302 measure outcome). We carried out an omnibus Chi-squared test to determine whether there
303 was a statistically significant condition effect on any item across the 8 assessment time points.

304 Secondary outcomes were analyzed using appropriate methods given the outcome type
305 (i.e. continuous, binary, ordinal) and repeated measures structure. The ATQ, PHQ-9, and the
306 SEQ scores were analyzed using a GEE similarly to the primary analyses. We estimated
307 condition effects on change in HAMD and change in GAD-7 between intake and post-
308 intervention using linear regression with an adjustment for baseline. We estimated risk
309 differences and Miettinen-Nurminen 95% confidence intervals (Miettinen and Nurminen,
310 1985) for HAMD response and remission, as well as for SCID diagnosis rates.

311 **Results**

312 *Baseline Characteristics and Participant Flow*

313 **Table 1** contains the baseline characteristics of the cohort by condition group. The
314 study randomized 40 participants between September 2023 and August 2024 with n=21
315 assigned to the CalmCBT condition and n=19 assigned to the ActiveCBT condition with
316 unequal numbers due to severity stratification (**Figure 1**).

317 *Session Completion*

318 Thirty-four out of forty (85%) participants completed $\geq 6/8$ CBT sessions with 33
319 completing all 8 sessions (82.5%). Across groups, 281/320 total visits were attended (87.8%).
320 By condition group, 15/19 (78.9%) ActiveCBT participants completed all 8 sessions versus
321 18/21 (85.7%) CalmCBT condition participants. As intended, the median was 7 days between

322 each weekly CBT session. Of the 7 participants who did not complete all 8 sessions, there
323 were two participants (one in each condition group) who completed 1, 2, and 3 sessions prior
324 to dropping out (shown in **Fig. 1**). There was also one ActiveCBT participant who only
325 completed 5 sessions but returned for a post-intervention visit. One participant was withdrawn
326 after the first session due to having previously unknown social relationships with study
327 therapists, whereas the remaining dropouts declined to continue.

328 *Condition Adherence*

329 As intended, participants assigned to the ActiveCBT condition had significantly higher
330 RPE (mean \pm SD, ActiveCBT: 13.0 ± 0.19 , CalmCBT: 6.22 ± 0.53 , $p < 0.001$) and heart rate
331 (ActiveCBT: 124.0 ± 17.5 bpm, CalmCBT: 74.9 ± 12.1 $p < 0.001$) than CalmCBT participants
332 during the pre-therapy condition periods.

333 *CBT Fidelity*

334 The mean overall score and standard deviation on the CTRS from Lyssn was $36.8 \pm$
335 5.1 (36.9 ± 5.4 Active, 36.7 ± 4.9 Calm, $p = 0.89$), demonstrating similarity of the fidelity of
336 the received therapy across the two groups.

337 *Primary Outcome Results – Target CBT Mechanisms*

338 **Table 2** contains results of the primary analyses for the key mechanism of change
339 outcomes. The average standardized effects on WAI total score and change in BADS were
340 0.14 and 0.43, respectively. Differences in the WAI Total score were driven entirely by the
341 Bond subscale such that the standardized effect on the WAI Bond subscale was 0.36.

342 *Working Alliance (WAI)*

343 The average effect on WAI Total was 1.02 (95% CI: -2.84 to 4.87; $p = 0.60$). This
344 effect favoring the ActiveCBT condition was predominately driven by the bond subscale.
345 Both groups demonstrate improving WAI Bond over time (**Figure 2**) with the ActiveCBT
346 condition group exhibiting a non-significantly higher alliance across all 8 assessments.

347 The item-specific analyses showed that items 3, 7, and 9 exhibited the largest
348 condition effects of 0.47, 0.23 and 0.22, respectively, with all three being from the Bond
349 subscale and favoring the ActiveCBT condition. There was a significant condition effect
350 when comparing to a nested mixed model without condition effects ($p=0.005$).

351 *Behavioral activation (BADs)*

352 The average effect on change in BADs was 7.78 (-1.31 to 16.86; $p=0.093$; **Table 2**).
353 Both condition groups exhibited improved BADs over time (**Figure 3**) with the ActiveCBT
354 condition group exhibiting a non-significantly larger improvement across all 8 assessments.

355 *Secondary Outcome Analyses*

356 The HAMD results indicate a modest general benefit for ActiveCBT over CalmCBT
357 conditions ($d=0.20$), limited benefit on response (risk difference: 0.12), and a large benefit on
358 remission (risk difference: 0.35 [0.01-0.62]; **Table 2**). There was not a significant group
359 difference for any of the other secondary outcomes.

360 *Adverse Events*

361 Overall, there were no unanticipated adverse events reported in either group across the
362 131 Active conditions, the 150 Calm conditions, or the subsequent 281 therapy sessions. At
363 post-intervention, 0/34 participants reported an adverse event had occurred during the
364 intervention. Three reportable events were recorded during the intervention period: a previous
365 social relationship with the therapist (resulted in study exit; classified as an unexpected
366 problem), a foot cramp (resolved during therapy session), and faintness from a blood draw
367 (resolved quickly with rest and hydration).

368 *Blinding Results*

369 Group membership was disclosed by 3 participants either during the interviews (0
370 ActiveCBT; 1 CalmCBT) or therapy (1 ActiveCBT; 1 CalmCBT). At post-intervention
371 among participants without a prior group disclosure, the therapist accurately predicted

372 condition membership 53% of the time (7/15 ActiveCBT, 10/17 CalmCBT), and the clinical
373 interviewer accurately predicted condition membership 58% of the time (9/16 ActiveCBT,
374 10/17 CalmCBT), neither of which were statistically significantly different from chance (i.e.,
375 50%).

376 **Discussion**

377 This randomized, controlled trial of the effects of exercise priming of CBT for
378 depressed adults in a major depressive episode showed that moderate exercise immediately
379 prior to therapy sessions (i.e., ActiveCBT vs. CalmCBT) non-significantly enhanced the
380 therapeutic bond and increased behavioral activation across therapy, two key factors
381 determining the efficacy of CBT. The degree of enhancement of working alliance
382 (particularly the bond subscale; $d=0.36$) and behavioral activation ($d=0.43$) met *a priori*-
383 defined benchmarks of both ≥ 0.35 , though confidence intervals included zero and findings
384 should be considered preliminary. Although exploratory, the HAMD results suggested a
385 potentially important remission benefit (i.e., HAMD <8) in the ActiveCBT over CalmCBT
386 groups after the intervention (69% vs 33%; $p<0.05$). The high adherence (87.8% of visits),
387 successful masking of assessors and therapists, similar therapy fidelity, and no adverse or
388 serious adverse events suggests highlight strengths of the study design and show that this
389 approach is feasible and safe for adults with depression. Overall, the present results met the
390 progression rules and support subsequent testing of this augmentation approach.

391 The current trial supports the use of exercise priming to enhance mechanisms of
392 change related to CBT's antidepressant effects. Both the bond component of working alliance
393 and behavioral activation were higher in the ActiveCBT over the CalmCBT group, exceeding
394 the pre-specified effect size milestone of 0.35. There is ongoing debate about whether
395 therapy's effectiveness is due to specific factors inherent to the therapy or non-specific factors
396 common across all therapies (Cuijpers et al., 2019b; Huibers and Cuijpers, 2015; Wampold,

397 2015; Wampold and Flückiger, 2023). However, the potential benefit of exercise priming to
398 both non-specific (therapeutic alliance) and specific (behavioral activation) factors is
399 noteworthy. This suggests that exercise priming could enhance the efficacy of any form of
400 psychotherapy by improving the therapeutic alliance and may also specifically benefit CBT
401 by increasing behavioral activation across treatment. Given that both pathways were
402 supported, exercise priming emerges as a promising, low-cost augmentation approach that
403 warrants rigorous testing in larger trials to determine its potential to boost psychotherapy (and
404 particularly CBT) efficacy.

405 The therapeutic alliance effects warrant careful consideration. Specifically, working
406 alliance was pre-specified as a primary mechanism, whereas the Bond subscale emerged as a
407 driver of alliance effects, exceeding the pre-specified effect-size threshold for ActiveCBT
408 even though the total WAI score did not (**Table 2**). This pattern is consistent with theoretical
409 expectations: the total WAI score combines bond, goals, and tasks, diluting any bond-specific
410 effect. Based on prior work (Meyer et al., 2022a, 2022b, 2016a), we hypothesized that
411 exercise would reduce state anhedonia and depressed mood and increase neuroplasticity
412 markers such as BDNF, creating a psychological state conducive to interpersonal
413 engagement. These changes are directly relevant to the bond dimension (e.g., “I feel that my
414 therapist appreciates me”), which reflects emotional connection rather than agreement on
415 tasks or goals. Acute exercise also improves emotion regulation and reduces stress reactivity
416 (Morava et al., 2024; Wang et al., 2024), and single sessions have been shown to enhance
417 social interaction and affiliative behaviors in clinical populations (Brand et al., 2018).
418 Together, these mechanisms provide a plausible basis for expecting exercise priming to
419 strengthen the therapeutic bond without necessarily influencing task or goal agreement.

420 Behavioral models of CBT suggest that increasing engagement with valued activities
421 and contact with environmental reward is a core mechanism of change. In a large

422 non-inferiority RCT, BA achieved outcomes comparable to CBT at 12 months, underscoring
423 the clinical relevance of activation-focused strategies (Richards et al., 2016). Meta-analytic
424 work further shows that BA not only reduces depressive symptoms but also increases
425 activation (e.g., BADS-indexed activation/approach (Stein et al., 2021)), supporting activation
426 as a plausible pathway of benefit. Given that BA is a core behavioral mechanism within CBT,
427 the between-session activation gains observed here align with BA's established change
428 pathway (more approach behavior and environmental reward) and with evidence that BA is
429 increases activation, suggesting that priming may have amplified clients' post-session
430 enactment of these CBT-embedded behaviors.

431 It is plausible that the improvements we observed in behavioral activation and
432 depressive symptoms reflect benefits of engaging in moderate-intensity exercise per se rather
433 than a mechanism unique to pre-CBT exercise. However, contemporary dose–response data
434 evidence (Noetel et al., 2024; Tang et al., 2024) shows that one exercise session per week is
435 unlikely to produce substantial antidepressant effects at the symptom level. Clinically
436 meaningful benefits typically emerge around 600-1000 MET-min/week of exercise, typically
437 achieved through 3–4 moderate-intensity sessions per week, well above the dose produced by
438 one 30-minute session (~90–180 MET-min). Therefore, although repeated exercise across the
439 intervention may contribute to general symptom improvement, the acute, session-proximal
440 mechanisms we targeted remain the more plausible explanation for the observed pre-CBT
441 effects than an antidepressant response generated from a once-weekly exercise dose.

442 Early alliance development is critical for CBT outcomes, with alliance typically
443 peaking in sessions 3–4 and strongly predicting symptom change (Horvath et al., 2011;
444 Wampold, 2015; Wampold and Flückiger, 2023). Prior research also shows that bond
445 specifically relates to CBT outcomes (Zimmermann et al., 2021). In the present trial, the
446 largest group differences in bond occurred early in treatment (**Figure 2**), suggesting that

447 exercise priming may accelerate the formation of a strong therapeutic relationship during this
448 crucial window. Although these bond-specific effects should be interpreted cautiously given
449 the sample size and confidence intervals, they align with mechanistic expectations and
450 highlight a promising pathway for enhancing psychotherapy engagement.

451 Importantly, the magnitude of the benefits are potentially meaningful in the context of
452 recent therapy research. A meta-analysis of psychotherapy dismantling trials for depression
453 indicates a modest $d=0.21$ effect size for the added benefit of therapies that include the
454 purportedly key therapy factors compared to therapies without (Cuijpers et al., 2019a).
455 Therefore, the relative benefits of exercise priming in the present trial of 0.36 and 0.43 may
456 have meaningful benefits in augmenting therapy if these effects on candidate mechanisms
457 translate into effects on depression. The small sample size requires cautious interpretation of
458 the present data, though provides compelling support for larger trials.

459 Although exploratory, the interviewer-assessed depression remission results suggests
460 an important clinical benefit. Remission rates according to the interviewer-administered
461 HAMD were significantly different between groups with 69% in the ActiveCBT group and
462 33% in the CalmCBT group achieving remission ($HAMD < 8$). This is encouraging as post-
463 treatment symptom severity is a significant predictor of the likelihood of relapse (Thase et al.,
464 1992; Wojnarowski et al., 2019). If these preliminary results showing a low general rate of
465 depressive symptoms and high remission after exercise-primed therapy is confirmed in larger
466 trials or persists at longer-term follow-up, exercise priming holds promise to meaningfully
467 increase the short- and long-term efficacy of psychotherapy for depression.

468 The design and execution of this trial provide strong internal validity and lead to
469 relatively high confidence in the results albeit within the context of the small sample size. The
470 CalmCBT comparator condition was time- and attention-matched with no group differences
471 in CBT quality (see Lyssn results) and provided strong clinical equipoise, which is missing

472 with most comparator conditions (Mohr et al., 2009). Additionally, we successfully masked
473 the therapist and clinical interviewers to treatment allocation. Further, the structured reporting
474 and zero adverse events during this trial highlights the safety of this approach. Finally,
475 adherence was high with only 3 dropouts/group for a total dropout rate of 15%, below the 20-
476 40% who do not complete therapy in community settings (Fenger et al., 2011; Gersh et al.,
477 2017). Overall, this trial's high internal validity lends confidence to its directional support of
478 exercise priming increasing working mechanisms of therapy and remission rates.

479 Nevertheless, the trial is not without limitations. Primarily, the trial was not designed
480 to provide an efficacy test, but rather to determine the plausibility of augmentation of working
481 alliance and behavioral activation via exercise priming. As a result, the sample size is low for
482 efficacy testing but was able to provide necessary effect size data to justify progression to a
483 larger trial to determine clinical efficacy. Although an interesting and related question, we did
484 not test whether uncoupled, once-weekly exercise alone augments CBT, rather, our trial
485 examined the clinically relevant question of session-proximal (pre-session) exercise as a
486 real-time priming strategy. Additionally, the exclusion criteria (e.g., BMI cutoff, some
487 comorbid mental health conditions) and limited participant heterogeneity limit
488 generalizability. Further, the lack of follow-up prevents examination of the durability of
489 potential benefits on relapse rates.

490

491 **Conclusion**

492 This 40-person randomized controlled trial of 8 weeks of moderate intensity acute
493 exercise priming compared to quiet rest immediately before standardized CBT sessions, found
494 sufficient directional engagement of an increased therapeutic bond and greater self-reported
495 behavioral activation in the exercise priming condition with potential benefits on depression
496 remission. Although these results should be interpreted cautiously considering the small

497 sample size and confidence intervals on mechanistic findings that include zero, they met a
498 priori-defined benchmarks of directional mechanistic signals and warrant further study of this
499 approach. Further, signals in both non-specific (therapeutic bond) and specific (behavioral
500 activation) working mechanisms of therapy success provide potential generalizability of the
501 exercise priming approach to other therapies while also highlighting its potential as a safe and
502 accessible augmentation approach to specifically increasing the antidepressant effects of CBT.

503 **References**

- 504 Alexopoulos, G.S., Raue, P.J., Gunning, F., Kiosses, D.N., Kanellopoulos, D., Pollari, C., Banerjee, S.,
505 Arean, P.A., 2016. "Engage" Therapy: Behavioral Activation and Improvement of Late-Life
506 Major Depression. *Am. J. Geriatr. Psychiatry* 24, 320–326.
507 <https://doi.org/10.1016/j.jagp.2015.11.006>
- 508 Arnow, B.A., Steidtmann, D., Blasey, C., Manber, R., Constantino, M.J., Klein, D.N., Markowitz, J.C.,
509 Rothbaum, B.O., Thase, M.E., Fisher, A.J., Kocsis, J.H., 2013. The relationship between the
510 therapeutic alliance and treatment outcome in two distinct psychotherapies for chronic
511 depression. *J. Consult. Clin. Psychol.* 81, 627–638. <https://doi.org/10.1037/a0031530>
- 512 Blue planet II, 2017. , Blue planet (TV series). BBC Earth, London, England.
- 513 Borg, G., 1998. Borg's perceived exertion and pain scales. Human Kinetics, Champaign, IL, US.
- 514 Brand, S., Colledge, F., Ludyga, S., Emmenegger, R., Kalak, N., Sadeghi Bahmani, D., Holsboer-
515 Trachsler, E., Pühse, U., Gerber, M., 2018. Acute Bouts of Exercising Improved Mood,
516 Rumination and Social Interaction in Inpatients With Mental Disorders. *Front. Psychol.* 9.
517 <https://doi.org/10.3389/fpsyg.2018.00249>
- 518 Bryant, R.A., Dawson, K.S., Azevedo, S., Yadav, S., Cahill, C., Kenny, L., Maccallum, F., Tran, J., Rawson,
519 N., Tockar, J., Garber, B., Keyan, D., 2023. Augmenting trauma-focused psychotherapy for
520 post-traumatic stress disorder with brief aerobic exercise in Australia: a randomised clinical
521 trial. *Lancet Psychiatry* 10, 21–29. [https://doi.org/10.1016/S2215-0366\(22\)00368-6](https://doi.org/10.1016/S2215-0366(22)00368-6)
- 522 Chang, Y.-K., Ren, F.-F., Li, R.-H., Ai, J.-Y., Kao, S.-C., Etnier, J.L., 2025. Effects of acute exercise on
523 cognitive function: A meta-review of 30 systematic reviews with meta-analyses. *Psychol. Bull.*
524 151, 240–259. <https://doi.org/10.1037/bul0000460>
- 525 Cohen, J., 1969. *Statistical Power Analysis for the Behavioral Sciences*, 1st Edition. ed. Academic
526 Press, New York and London.
- 527 Cuijpers, P., Cristea, I.A., Karyotaki, E., Reijnders, M., Hollon, S.D., 2019a. Component studies of
528 psychological treatments of adult depression: A systematic review and meta-analysis.
529 *Psychother. Res.* 29, 15–29. <https://doi.org/10.1080/10503307.2017.1395922>
- 530 Cuijpers, P., Karyotaki, E., Weitz, E., Andersson, G., Hollon, S.D., van Straten, A., 2014. The effects of
531 psychotherapies for major depression in adults on remission, recovery and improvement: A
532 meta-analysis. *J. Affect. Disord.* 159, 118–126. <https://doi.org/10.1016/j.jad.2014.02.026>
- 533 Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C.H., Cipriani, A., Furukawa, T.A., 2020. A network meta-
534 analysis of the effects of psychotherapies, pharmacotherapies and their combination in the
535 treatment of adult depression. *World Psychiatry* 19, 92–107.
536 <https://doi.org/10.1002/wps.20701>
- 537 Cuijpers, P., Quero, S., Noma, H., Ciharova, M., Miguel, C., Karyotaki, E., Cipriani, A., Cristea, I.A.,
538 Furukawa, T.A., 2021. Psychotherapies for depression: a network meta-analysis covering
539 efficacy, acceptability and long-term outcomes of all main treatment types. *World Psychiatry*
540 20, 283–293. <https://doi.org/10.1002/wps.20860>
- 541 Cuijpers, P., Reijnders, M., Huibers, M.J.H., 2019b. The Role of Common Factors in Psychotherapy
542 Outcomes. *Annu. Rev. Clin. Psychol.* 15, 207–231. <https://doi.org/10.1146/annurev-clinpsy-050718-095424>
- 544 Cully, J.A., Teten, A.L., 2008. *A therapist's guide to brief cognitive behavioral therapy*. Department of
545 Veterans Affairs South Central MIRECC, Houston.
- 546 Fenger, M., Mortensen, E.L., Poulsen, S., Lau, M., 2011. No-shows, drop-outs and completers in
547 psychotherapeutic treatment: Demographic and clinical predictors in a large sample of non-
548 psychotic patients. *Nord. J. Psychiatry* 65, 183–191.
549 <https://doi.org/10.3109/08039488.2010.515687>
- 550 First, M., Williams, J., Karg, R., Spitzer, R., 2015. *Structured Clinical Interview for DSM-5, Clinical Trials*
551 *Version*. American Psychiatric Association, Arlington, VA.

552 Gersh, E., Hallford, D.J., Rice, S.M., Kazantzis, N., Gersh, H., Gersh, B., McCarty, C.A., 2017. Systematic
553 review and meta-analysis of dropout rates in individual psychotherapy for generalized
554 anxiety disorder. *J. Anxiety Disord.* 52, 25–33. <https://doi.org/10.1016/j.janxdis.2017.10.001>
555 Hamilton, M., 1967. Development of a rating scale for primary depressive illness. *Br. J. Soc. Clin.*
556 *Psychol.* 6, 278–296.

557 Hatcher, R.L., Gillaspay, J.A., 2006. Development and validation of a revised short version of the
558 working alliance inventory. *Psychother. Res.* 16, 12–25.
559 <https://doi.org/10.1080/10503300500352500>

560 Hollon, S.D., Kendall, P.C., 1980. Cognitive self-statements in depression: Development of an
561 automatic thoughts questionnaire. *Cogn. Ther. Res.* 4, 383–395.
562 <https://doi.org/10.1007/BF01178214>

563 Horvath, A.O., Del Re, A.C., Flückiger, C., Symonds, D., 2011. Alliance in individual psychotherapy.
564 *Psychotherapy* 48, 9–16. <https://doi.org/10.1037/a0022186>

565 Huibers, M.J.H., Cuijpers, P., 2015. Common (Nonspecific) Factors in Psychotherapy, in: *The*
566 *Encyclopedia of Clinical Psychology.* American Cancer Society, pp. 1–6.
567 <https://doi.org/10.1002/9781118625392.wbecp272>

568 Imel, Z.E., Tanana, M.J., Soma, C.S., Hull, T.D., Pace, B.T., Stanco, S.C., Creed, T.A., Moyers, T.B.,
569 Atkins, D.C., 2024. Outcomes in Mental Health Counseling From Conversational Content With
570 Transformer-Based Machine Learning. *JAMA Netw. Open* 7, e2352590.
571 <https://doi.org/10.1001/jamanetworkopen.2023.52590>

572 Kanter, J.W., Mulick, P.S., Busch, A.M., Berlin, K.S., Martell, C.R., 2006. The Behavioral Activation for
573 Depression Scale (BADs): Psychometric Properties and Factor Structure. *J. Psychopathol.*
574 *Behav. Assess.* 29, 191. <https://doi.org/10.1007/s10862-006-9038-5>

575 Kessler, R.C., Petukhova, M., Sampson, N.A., Zaslavsky, A.M., Wittchen, H.-U., 2012. Twelve-month
576 and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United
577 States. *Int. J. Methods Psychiatr. Res.* 21, 169–184. <https://doi.org/10.1002/mpr.1359>

578 Khazanov, G.K., Xu, C., Dunn, B.D., Cohen, Z.D., DeRubeis, R.J., Hollon, S.D., 2020. Distress and
579 anhedonia as predictors of depression treatment outcome: A secondary analysis of a
580 randomized clinical trial. *Behav. Res. Ther.* 125, 103507.
581 <https://doi.org/10.1016/j.brat.2019.103507>

582 Kroenke, K., Spitzer, R.L., Williams, J.B.W., 2001. The PHQ-9. *J. Gen. Intern. Med.* 16, 606–613.
583 <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>

584 Lemmens, L.H.J.M., van Bronswijk, S.C., Peeters, F., Arntz, A., Hollon, S.D., Huibers, M.J.H., 2019.
585 Long-term outcomes of acute treatment with cognitive therapy v. interpersonal
586 psychotherapy for adult depression: follow-up of a randomized controlled trial. *Psychol.*
587 *Med.* 49, 465–473. <https://doi.org/10.1017/S0033291718001083>

588 Lorenzo-Luaces, L., German, R.E., DeRubeis, R.J., 2015. It’s complicated: The relation between
589 cognitive change procedures, cognitive change, and symptom change in cognitive therapy for
590 depression. *Clin. Psychol. Rev., Psychological Interventions for Depression* 41, 3–15.
591 <https://doi.org/10.1016/j.cpr.2014.12.003>

592 Manos, R.C., Kanter, J.W., Busch, A.M., 2010. A critical review of assessment strategies to measure
593 the behavioral activation model of depression. *Clin. Psychol. Rev.* 30, 547–561.
594 <https://doi.org/10.1016/j.cpr.2010.03.008>

595 Meyer, J.D., Kelly, S.J., Gidley, J.M., Lansing, J.E., Smith, S.L., Churchill, S.L., Thomas, E.B., Goldberg,
596 S.B., Abercrombie, H.C., Murray, T.A., 2024. Protocol for a randomized controlled trial:
597 exercise-priming of CBT for depression (the CBT+ trial). *Trials* 25, 663.

598 Meyer, J.D., Koltyn, K.F., Stegner, A.J., Kim, J.-S., Cook, D.B., 2016a. Relationships between serum
599 BDNF and the antidepressant effect of acute exercise in depressed women.
600 *Psychoneuroendocrinology* 74, 286–294.

601 Meyer, J.D., Koltyn, K.F., Stegner, A.J., Kim, J.-S., Cook, D.B., 2016b. Influence of exercise intensity for
602 improving depressed mood in depression: a dose-response study. *Behav. Ther.* 47, 527–537.

603 Meyer, J.D., Murray, T.A., Brower, C.S., Cruz-Maldonado, G.A., Perez, M.L., Ellingson, L.D., Wade,
604 N.G., 2022a. Magnitude, timing and duration of mood state and cognitive effects of acute
605 moderate exercise in major depressive disorder. *Psychol. Sport Exerc.* 61, 102172.

606 Meyer, J.D., Perkins, S.L., Brower, C.S., Lansing, J.E., Slocum, J.A., Thomas, E.B., Murray, T.A., Lee, D.,
607 Wade, N.G., 2022b. Feasibility of an exercise and CBT intervention for treatment of
608 depression: a pilot randomized controlled trial. *Front. Psychiatry* 13, 799600.

609 Miettinen, O., Nurminen, M., 1985. Comparative analysis of two rates. *Stat. Med.* 4, 213–226.
610 <https://doi.org/10.1002/sim.4780040211>

611 Mohr, D.C., Spring, B., Freedland, K.E., Beckner, V., Arean, P., Hollon, S.D., Ockene, J., Kaplan, R.,
612 2009. The Selection and Design of Control Conditions for Randomized Controlled Trials of
613 Psychological Interventions. *Psychother. Psychosom.* 78, 275–284.
614 <https://doi.org/10.1159/000228248>

615 Morava, A., Dillon, K., Sui, W., Alushaj, E., Prapavessis, H., 2024. The effects of acute exercise on
616 stress reactivity assessed via a multidimensional approach: a systematic review. *J. Behav.*
617 *Med.* 47, 545–565. <https://doi.org/10.1007/s10865-024-00470-w>

618 Noetel, M., Sanders, T., Gallardo-Gómez, D., Taylor, P., Del Pozo Cruz, B., van den Hoek, D., Smith,
619 J.J., Mahoney, J., Spathis, J., Moresi, M., Pagano, R., Pagano, L., Vasconcellos, R., Arnott, H.,
620 Varley, B., Parker, P., Biddle, S., Lonsdale, C., 2024. Effect of exercise for depression:
621 systematic review and network meta-analysis of randomised controlled trials. *BMJ* 384,
622 e075847. <https://doi.org/10.1136/bmj-2023-075847>

623 Polyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., Schroeter, M.L., 2015. BDNF
624 as a biomarker for successful treatment of mood disorders: A systematic & quantitative
625 meta-analysis. *J. Affect. Disord.* 174, 432–440. <https://doi.org/10.1016/j.jad.2014.11.044>

626 Posner, K., Brent, D., Lucas, C., Gould, M., Stanley, B., Brown, G., Fisher, P., Zelazny, J., Burke, A.,
627 Oquendo, M., 2008. Columbia-suicide severity rating scale (C-SSRS). *N. Y. NY Columbia Univ.*
628 *Med. Cent.* 10, 2008.

629 Richards, D.A., Ekers, D., McMillan, D., Taylor, R.S., Byford, S., Warren, F.C., Barrett, B., Farrand, P.A.,
630 Gilbody, S., Kuyken, W., O’Mahen, H., Watkins, E.R., Wright, K.A., Hollon, S.D., Reed, N.,
631 Rhodes, S., Fletcher, E., Finning, K., 2016. Cost and Outcome of Behavioural Activation versus
632 Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-
633 inferiority trial. *The Lancet* 388, 871–880. [https://doi.org/10.1016/S0140-6736\(16\)31140-0](https://doi.org/10.1016/S0140-6736(16)31140-0)

634 Schmitter, M., Rubin, M., Smits, J.A.J., Reijnen, S.E., de Ruiter-Blijdorp, E.D., van den Berg, M.M.A., de
635 Jong-Dinar, R., Spijker, J., Vrijzen, J.N., 2025. Exercise prior to cognitive behavior therapy
636 sessions for depression: a feasibility pilot study. *Cogn. Behav. Ther.* 0, 1–13.
637 <https://doi.org/10.1080/16506073.2024.2449088>

638 Stein, A.T., Carl, E., Cuijpers, P., Karyotaki, E., Smits, J.A.J., 2021. Looking beyond depression: a meta-
639 analysis of the effect of behavioral activation on depression, anxiety, and activation. *Psychol.*
640 *Med.* 51, 1491–1504. <https://doi.org/10.1017/S0033291720000239>

641 Stiles, W.B., 1980. Measurement of the impact of psychotherapy sessions. *J. Consult. Clin. Psychol.*
642 48, 176–185. <https://doi.org/10.1037/0022-006X.48.2.176>

643 Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V.L., Taylor, R.,
644 Mantingh, T., Angel, V. de, Patrick, F., Cleare, A.J., Young, A.H., 2019. Augmentation therapies
645 for treatment-resistant depression: systematic review and meta-analysis. *Br. J. Psychiatry*
646 214, 42–51. <https://doi.org/10.1192/bjp.2018.233>

647 Tang, L., Zhang, L., Liu, Y., Li, Y., Yang, L., Zou, M., Yang, H., Zhu, L., Du, R., Shen, Y., Li, H., Yang, Y., Li,
648 Z., 2024. Optimal dose and type of exercise to improve depressive symptoms in older adults:
649 a systematic review and network meta-analysis. *BMC Geriatr.* 24, 505.
650 <https://doi.org/10.1186/s12877-024-05118-7>

651 Thase, M.E., Simons, A.D., McGeary, J., Cahalane, J.F., Hughes, C., Harden, T., Friedman, E., 1992.
652 Relapse after cognitive behavior therapy of depression: potential implications for longer
653 courses of treatment. *Am. J. Psychiatry* 149, 1046–1052.
654 <https://doi.org/10.1176/ajp.149.8.1046>

655 Vittengl, J.R., Clark, L.A., Dunn, T.W., Jarrett, R.B., 2007. Reducing relapse and recurrence in unipolar
656 depression: A comparative meta-analysis of cognitive-behavioral therapy's effects. *J. Consult.
657 Clin. Psychol.* 75, 475–488. <https://doi.org/10.1037/0022-006X.75.3.475>

658 Wampold, B.E., 2015. How important are the common factors in psychotherapy? An update. *World
659 Psychiatry* 14, 270–277. <https://doi.org/10.1002/wps.20238>

660 Wampold, B.E., Flückiger, C., 2023. The alliance in mental health care: conceptualization, evidence
661 and clinical applications. *World Psychiatry* 22, 25–41. <https://doi.org/10.1002/wps.21035>

662 Wang, X., Liu, T., Jin, X., Zhou, C., 2024. Aerobic exercise promotes emotion regulation: a narrative
663 review. *Exp. Brain Res.* 242, 783–796. <https://doi.org/10.1007/s00221-024-06791-1>

664 Williams, J.B.W., Kobak, K.A., Bech, P., Engelhardt, N., Evans, K., Lipsitz, J., Olin, J., Pearson, J., Kalali,
665 A., 2008. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale: *Int. Clin.
666 Psychopharmacol.* 23, 120–129. <https://doi.org/10.1097/YIC.0b013e3282f948f5>

667 Wojnarowski, C., Firth, N., Finegan, M., Delgadillo, J., 2019. Predictors of depression relapse and
668 recurrence after cognitive behavioural therapy: a systematic review and meta-analysis.
669 *Behav. Cogn. Psychother.* 47, 514–529. <https://doi.org/10.1017/S1352465819000080>

670 Young, J.E., Beck, A.T., 1980. Cognitive therapy scale. Unpubl. Manuscr. Univ. Pa.

671 Zimmerman, M., Martinez, J.H., Young, D., Chelminski, I., Dalrymple, K., 2013. Severity classification
672 on the Hamilton Depression Rating Scale. *J. Affect. Disord.* 150, 384–388.
673 <https://doi.org/10.1016/j.jad.2013.04.028>

674 Zimmermann, D., Wampold, Bruce E., Rubel, Julian A., Schwartz, Brian, Poster, Kaitlyn, Schilling, Viola
675 N. L. S., Deisenhofer, Anne-Katharina, Hehlmann, Miriam I., Gómez Penedo, Juan Martín, and
676 Lutz, W., 2021. The influence of extra-therapeutic social support on the association between
677 therapeutic bond and treatment outcome. *Psychother. Res.* 31, 726–736.
678 <https://doi.org/10.1080/10503307.2020.1847344>

679 Zucker, N.L., Strauss, G.P., Smyth, J.M., Scherf, K.S., Brotman, M.A., Boyd, R.C., Choi, J., Davila, M.,
680 Ajilore, O.A., Gunning, F., Schweitzer, J.B., 2025. Experimental Therapeutics: Opportunities
681 and Challenges Stemming From the National Institute of Mental Health Workshop on Novel
682 Target Discovery and Psychosocial Intervention Development. *Perspect. Psychol. Sci.* 20,
683 485–502. <https://doi.org/10.1177/17456916231197980>

684

Figure legends

Fig. 1. CONSORT diagram for CBT+ trial from screening to post-intervention.

Abbreviations: BMI: body mass index, PHQ2: Patient Health Questionnaire-2, PHQ8: Patient Health Questionnaire-8, CSSRS: Columbia-Suicide Severity Rating Scale, MDD: major depressive disorder, CBT: cognitive behavioral therapy.

Fig. 2. Estimated expected working alliance inventory (WAI) Bond with 95% confidence intervals (A) by condition across all eight sessions, and (B) the relative difference between the groups across sessions.

Fig. 3. Estimated expected change in behavioral activation for depression scale (BADS) total from week 1 with 95% confidence intervals (A) by condition across all eight sessions, and (B) the relative difference between the groups across sessions.